Disclosure: This educational guide is published by AirMedFit, which lists consultation services. It does not determine which medicine, dose or switching schedule is appropriate for you.
Switching GLP-1 medicines starts with identifying the exact old and proposed products and getting a written plan from the prescriber. A dose-conversion chart cannot account for your indication, treatment interruption, side effects, other medicines or the device you will receive. Do not improvise a switch from another person's experience.
Identify the product before discussing the transition
Record the brand and active ingredient, route, presentation, strength and actual last dose date. Include missed doses and the reason for considering a change. Different brands, indications and presentations should not be treated as interchangeable instructions.
The Zepbound prescribing information revised August 2026 says coadministration with another tirzepatide-containing product or any GLP-1 receptor agonist is not recommended. That statement is not a universal interval for switching. Ask the prescriber to specify the last dose of the old product and the first dose of the new one, including what to do if the new supply is delayed.
Ask for a plan you can read back
-
Goal: Why change products, and what outcome will determine whether the new plan is working?
-
Prescription: What exact medicine, starting prescription, route and device are intended? Which current product instructions should I follow?
-
Interruption: How do my missed doses, time off treatment or previous intolerance affect the plan?
-
Other medicines: Does the change require a separate plan for insulin, other glucose-lowering treatment, contraception or any other medicine I take? Who will explain and document it?
-
Review: When is my individual follow-up, which observations matter, and how do I reach the team sooner?
-
Practical access: Is the intended product covered and available, and who resolves a prescription or dispensing mismatch?
These are questions for the treating team, not instructions to alter medicines yourself. A fixed number of weeks on the old medicine does not, by itself, settle the new prescription.
Make device and concentration questions explicit
If the new supply looks different, ask the dispensing pharmacist to identify it and demonstrate the instructions for that exact presentation. Do not transfer a pen setting, syringe “unit” number or volume from the old product to a different concentration.
FDA's information on unapproved GLP-1 drugs distinguishes compounded medicines from FDA-approved products and describes dosing concerns. Ask which status applies, which pharmacy dispenses it and why that specific product is proposed. Registration is not approval of a compounded product.
Know which symptoms need help sooner
Do not wait for the planned review if you have severe or persistent abdominal pain, repeated vomiting or trouble keeping fluids down; seek prompt medical assessment. Trouble breathing or swelling of the face, lips, tongue or throat needs emergency help. Zepbound's labeling describes pancreatitis, dehydration-related kidney injury and serious allergic reactions. Ask the team for the exact product's symptom and next-dose instructions, including a low-blood-sugar plan if relevant to your other treatment.
An optional private handover note
“My current product is [name]; my last actual dose was [date]; interruptions or symptoms were [details]; I want to discuss a change because [reason]. Please write the intended new product, stop/start plan, device instructions, review date and urgent contact route.” No tracking period is required before requesting care.
For appointment preparation, see our weight-loss consultation questions. To ask about a visit, review the current consultation listing and confirm scope, eligibility, costs and follow-up before booking. This guide does not promise that a particular prescription or service is available.